RESEARCH
Overview
There are
6.4 million psoriasis patients in the United States. Fifty-eight
percent of those with psoriasis experience inadequate treatment
because current major therapies are sometimes ineffective, unavailable,
or unsatisfactory. Current major therapies often help psoriasis,
but can increase skin aging, skin cancer, liver or kidney toxicity,
blood lipids, or blood pressure. We are committed to helping develop
improved therapeutic approaches without the above drawbacks.
Our
Dermatology faculty have established a full spectrum of projects
which will benefit patients who suffer from psoriasis. Our highly
experienced staff takes great pride in providing top quality,
well-established therapies with proven efficacy. We work hard
to obtain advanced treatments that we believe are safe but have
a strong chance of benefit. Thus we can provide early access
for our patients to newly developing therapies that are not yet
generally available. We are also one of a few centers worldwide
with psoriasis awards from the National Institutes of Health,
the Dermatology Foundation, and the Department of Veterans Affairs
to research how psoriasis lesions are caused, and to develop
entirely new ways of treating psoriasis without the side effects
of our current therapies.
The Murdough
Family Center for Psoriasis, newly created by a generous gift from
the Murdough Foundation, will allow us to bring benefit to more
patients with the disease. The Murdough Family Center for Psoriasis
incorporates both the psoriasis research and treatment efforts
of the medical center, and creates new community interfaces and
a complete approach to both the mind and the body aspects of psoriasis.
Center for Research
Translation (CORT)
The National Institute of Health (NIH) recently awarded Case Western Reserve University and University Hospitals Case Medical Center a $6.3 millon award to establish a Center of Research Translation (CORT) in Psoriasis. This is one of the largest grants ever given to a medical institution in the United States for the study of psoriasis.
NIAMS Press Release
CASE Press Release
A Center
of Research Translation (CORT) in Psoriasis based at University
Hospitals Case Medical Center will integrate a strong psoriasis and
skin
disease research base with a large existing cohort of psoriasis
patients. $5M from the new University Hospitals Murdough Family
Center for Psoriasis will further increase the capabilities and
geography of the clinical referral network, and in combination
with $2M from Case School of Medicine for recruitment in psoriasis,
these resources comprise a substantial institutional commitment
to the CORT. The Skin Diseases Research Center’s cutaneous
biology infrastructure and experience will accelerate the Case
Psoriasis CORT’s advances for psoriasis patient benefit.
The translational projects envisioned will test innovative therapeutic
interventions in psoriasis that are based upon new mechanistic
findings. They also provide new pathogenetic information using
biologic samples from patients and animal models. It is intended
that each Project will generate therapeutic modalities that change
the treatment of psoriasis patients.
Project 1: Pc4 PDT for Psoriasis
PI: Elma Baron,
MD
This is a novel photodynamic therapy (PDT) Phase I mechanistic, safety,
and preliminary efficacy study which also develops a real-time patient-optimized
therapy device.
Project 2:S100 A8/A9 and Macrophages
in Psoriasis
PI:
Kevin D. Cooper, MD
This
is
a basic study that determines novel roles for S100 proteins in the pathogenesis
of psoriasis, including
proof-of-principle testing of S100 and macrophage interplay in
psoriasis skin on xenogenic
transplants.
Project 3: VEGF Influences Keratinocyte-Immunocyte
Interactions in Psoriasiform Dermatitis
PI:
Nicole Ward, PhD
This project takes
advantage of a novel transgenic mouse model of psoriasiform dermatitis
to examine the
potential
role of VEGF, S100 A8/9 and vascular changes exacerbating psoriasis.
Psoriasis Database Study Participants
Thank you for your interest in enrolling in our database. The purpose of the database is to gather comprehensive data on your personal and medical history, detailed history of your psoriasis, including the current and past treatments you have received, and medical history of your family members including psoriasis. Information gathered will be stored in an electronic database, which may help researchers develop a better understanding of this disease, and thus lead to future studies improving the management of psoriasis. If you have previously consented (in person or by phone) for the study entitled "Epidemiology, comorbidities, risk factors, and treatment profile of psoriasis patients (UH IRB # 03-07-31)," click here to start the online survey.
Back
to top
Psoriasis Presentations
2007
Advances in the Treatment of Psoriasis With Biologic Therapies
Virginia Beach Dermatology Grand Rounds, Virginia Beach, VA
Neil J. Korman, MD PhD
Combination Immunosuppressive Therapies: The Promise and The Peril
American Academy of Dermatology, Washington DC
Neil J. Korman, MD PhD
How and When To Use Scary Drugs
American Academy of Dermatology, Washington DC
Neil J. Korman, MD PhD
2006
Alefacept: The Newest Developments
Hawaii Dermatology Seminar, Kauai, HI
Neil J. Korman, MD PhD
Biologics for Psoriasis: A Mechanism of Action Based Approach
American Academy of Dermatology, San Francisco, CA
Neil J. Korman,
MD PhD
2005
Biologics in Psoriasis: A Clinical and Laboratory Approach
American Academy of Dermatology, New Orleans, LA
Neil J. Korman, MD PhD
Investigating Selective T–Cell
Targeting in Psoriasis: Optimizing Outcomes in Clinical Practice
Skin Disease Education Foundation, Maui, HI
Neil J. Korman, MD PhD
Update on Biological Therapies for the Treatment of Psoriasis
TriServices Military Dermatology Conference, Bethesda, MD
Neil J. Korman, MD PhD
Classical Immunomodulatory Therapies
American Academy of Dermatology Session. Chicago, IL
Neil J. Korman, MD PhD
Biologics in the Treatment of Psoriasis and Other Allied Conditions
TNF and Beyond: Treatment of Autoimmune and Inflammatory Disorders Summit,
Cleveland, OH
Neil J. Korman, MD PhD
An Open Label Dose Escalation Study of Alefacept for Adults with
Chronic Plaque Psoriasis
American Dermatologic Association, Greensboro, NC
Neil J. Korman, MD PhD
Advances in the Treatment of Psoriasis With Biologic Therapies
University of Minnesota, Minneapolis, MN
Neil J. Korman, MD PhD
Biologic Therapies for Psoriasis: Where Are We Today?
University of Louisville, Louisville, KY
Neil J. Korman,
MD PhD
2004
Biologics in Psoriasis: A Clinical and Laboratory Approach
American Academy of Dermatology, Washington, DC
Neil J. Korman, MD PhD
New Biologic Therapies in the Treatment of Psoriasis
Vanderbilt University, Nashville, TN
Neil J. Korman, MD PhD
What Every Dermatologist Needs to Know About the Treatment of Psoriasis
American Academy of Dermatology Symposium, Las Vegas, NV
Neil J. Korman, MD PhD
Efalizumab Treatment for Patients with Psoriasis: Real World Approach
Skin Disease Education Foundation, Phoenix, AR
Neil J. Korman, MD PhD
The Newest Biologic Therapies for the Treatment of Psoriasis
Univ of Connecticut, Farmington, CT
Neil J. Korman, MD PhD
Alefacept: New Developments
Psoriasis Course at American Academy of Dermatology, NY, NY
Neil J. Korman, MD PhD
21st Century Immunomodulatory Therapies
New Therapies Course at American Academy of Dermatology, NY, NY
Neil J. Korman, MD PhD
Systemic Therapies for the Treatment of Psoriasis
Skin Disease Education Foundation, Santa Fe, NM
Neil J. Korman, MD PhD
Alefacept: A Potentially Remittive Therapy for the Treatment of
Psoriasis
Skin Disease Education Foundation, Santa Fe, NM
Neil J. Korman, MD PhD
Practical Considerations in the Treatment of Patients with Psoriasis
American Academy of Dermatology Symposium, Chicago, IL
Neil J. Korman, MD PhD
What Every Dermatologist Needs to Know About the Treatment of Psoriasis
American Academy of Dermatology Symposium, Chicago, IL
Neil J. Korman, MD PhD
Treatment of Psoriasis With an Emphasis on New Biologic Therapies
Piedmont Dermatology Society, Blowing Rock, NC
Neil J. Korman,
MD PhD
Back to top
Psoriasis Publications
Bata-Csorgo Z, Hammerberg C, Voorhees
JJ, and Cooper KD. 1993. Flow cytometric identification of proliferative
subpopulations within normal human epidermis and the localization
of the primary hyperproliferative population in psoriasis. J Exp
Med 178: 1271-81.
Bata-Csorgo Z, Hammerberg C, Voorhees
JJ, and Cooper KD. 1995. Kinetics and regulation of human keratinocyte
stem cell growth in short term primary ex vivo culture; growth
factors cooperative with IFN gamma from psoriatic lesional T lymphocyte
timulate proliferation among psoriatic uninvolved, but not normal,
stem keratinocytes. J Clin Invest 95: 317-27.
Skov L, Chan LS, Fox DA, Larsen JK,
Voorhees JJ, Cooper KD, and Baadsgaard O. 1997. Lesional psoriatic
T cells contain the capacity to induce a T cell activation molecule
CDW60 on normal keratinocytes. Am J Pathol 150: 675-83.
Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo
Z, and Cooper KD. 1998. Identification and quantitation of interferon-producing
T cells in psoriatic lesions: Localization to both CD4+ and CD8+
subsets. J Invest Dermatol 111: 1072-8.
Bata-Csorgo Z, Cooper KD, Voorhees JJ,
and Hammerberg C. 1998. Fibronectin and 5 integrin regulate keratinocyte
stem cell recycling: A mechanism for increased fibronectin potentiation
of T cell lymphokine-driven keratinocytic stem cell hyperproliferation
in psoriasis. J Clin Invest 101:1509-18.
Ting KM, McCormick TS, Hammerberg C,
Chen G, Gilliam AC, and Cooper KD. 2000. Overexpression of the
oncofetal Fn variant containing the EDA splice-in segment in the
dermal-epidermal junction of the psoriatic uninvolved skin. Journal
of Investigative Dermatology 114:706-11.
McCormick TS, Stevens SR, and Kang K.
2000. Macrophages and cutaneous inflammation. Nature Biotechnology
18:25-6.
Chen G, McCormick TS, Hammerberg C,
Ryder-Diggs S, Stevens SR, and Cooper KD. 2001. Basal keratinocytes
from uninvolved psoriatic skin exhibit accelerated spreading and
focal adhesion kinase (FAK) responsiveness to fibronectin. Journal
of Investigative Dermatology 117:1538-1545.
Gordon KB and McCormick TS. 2003. Evolution
of biologic therapies for the treatment of psoriasis. Skinmed 2(5):286-94.
Kauffman CL, Aria N, Toichi E, McCormick
TS, Cooper KD, Gottlieb AB, Everitt DE, Fredereick B, Zhu Y, Graham
MA, Pendley CE, and Mascelli MA. 2004. A phase I study evaluating
the safety, pharmacokinetics, and clinical response of human IL-12
p40 antibody in subjects with plaque psoriasis. Journal of Investigative
Dermatology 123(6): 1037-44.
Sugiyama H, Gyulai R, Toichi E, Garaczi
E, Shimada S, Stevens SR, McCormick TS, and Cooper KD. 2005.
Dysfunctional blood and target tissue CD4+ CD25high regulatory T
cells in psoriasis:
Mechanism underlying unrestrained pathogenic effector T cell
proliferation. Journal of Immunology 174(1): 164-73.
Moul DK and Korman NJ. 2005. The Early
Signs and Symptoms of Psoriatic Arthritis: The Importance of Early
Evaluation
and Treatment. Psoriasis Forum,
11:4-6.
Kagen M, McCormick T, and Cooper KD.
2006. Regulatory T cells in psoriasis. Ernst Schering Res Foundation
Workshop. 56:193-209.
Toichi E, Torres G, McCormick TS, Chang
T, Mascelli MA, Kaufmann CL, Aria N, Gottlieb AB, Everitt DE, Frederick
B, Pendley CE, and Cooper KD. 2006. An anti-IL-12 p40 antibody
downregulates type 1 cytokines, chemokines and IL-12/IL-23 in psoriasis.
Journal of Immunology 177(7): 4917-26.
Korman NJ and Moul DK. 2005. Alefacept
for the treatment of psoriasis. Sem Cut Med Surg 24: 10-8.
Voskas D, Jones N, Van Slyke P, Sturk
C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward
N, Cruz M, Jones J, Kerbel RS, Jothy S, Dagnino L, Arbiser J, Klement
G, and Dumon DJ. 2005. A cyclosporine-sensitive psoriasis-like
disease produced in Tie2 transgenic mice. Am J of Pathology 166:
843-55.
Gordon K, Korman NJ, Frankel E, Wang
H, Jahreis A, and Zitnik R. 2006. Efficacy of etanercept in an
integrated database of patients with psoriasis. J Am Acad Dermatol
54: S101-6.
Routhouska SB and Korman NJ. 2006. Initiating
and monitoring patients on biologic therapy for psoriasis beyond
the FDA: Our more cautious approach. Psoriasis Forum 12: 12-5.
Pariser DM, Bagel J, Gelfand JM, Korman
NJ, Richlin CT, et al. National Psoriasis Foundation clinical consensus
on psoriasis disease severity. In Press, 2006.
Robinson MR and Korman NJ. The use of
biologics in psoriasis patients with co-morbidities. In Press,
2006.
Moul DK, Routhouska SB, Korman NJ . Open-Label, Single-Center, Safety Dose Escalation Trial of Alefacept for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. J Cutan Med Surg 2007; 11:132-136.
Robinson MR, Korman BD, Korman NJ . Combination Immunosuppressive Therapies: The Promise and The Peril. Arch Dermatol, 2007; 143:1053-1058.
DM Pariser, J Bagel, JM Gelfand, NJ Korman , CT Ritchlin, BE Strober, AS Van Voorhees, M Young, S Rittenberg , M Lebwohl, EJ Horn. National Psoriasis Foundation Clinical Consensus on Psoriasis Disease Severity: Arch Dermatol, 2007; 143:239-242.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Mark Lebwohl, Koo JYM, Elmets CA, Korman NJ , Beutner KR, Bhushan R. Guidelines of Care for the Diagnosis and Management of Psoriasis and Psoriatic Arthritis: Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis with Biologics. J Am Acad Dermatol; 2008; 58:826-850.
Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of Care for the Diagnosis and Management of Psoriasis and Psoriatic Arthritis Psoriatic Arthritis: Overview and Guidelines of Care for Treatment with an Emphasis on the Biologics. J Am Acad Dermatol; 2008; 58:851-864.
Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and Vaccinations in Patients Treated with Biologics for Psoriasis. J Am Acad Dermatol. 2008; 58:94-105
.jpg)
.jpg)
